<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03142516</url>
  </required_header>
  <id_info>
    <org_study_id>GEMCAD-16-03</org_study_id>
    <secondary_id>2017-001639-38</secondary_id>
    <nct_id>NCT03142516</nct_id>
  </id_info>
  <brief_title>FOLFIRI + Panitumumab First-line Treatment in Elderly Patients With Unresectable Metastatic Colorectal Cancer, RAS/BRAF Wild-type and Good Performance Status</brief_title>
  <acronym>OPALO</acronym>
  <official_title>A Phase II Trial to Evaluate the Efficacy and Safety of FOLFIRI + Panitumumab as First-line Treatment in Elderly Patients With RAS/BRAF Wild-type Unresectable Metastatic Colorectal Cancer and Good Performance Status</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grupo Espanol Multidisciplinario del Cancer Digestivo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pivotal S.L.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Grupo Espanol Multidisciplinario del Cancer Digestivo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To estimate progression-free survival at one year in elderly patients with RAS/BRAF wild-type
      unresectable mCRC and good performance status treated with FOLFIRI + panitumumab as
      first-line therapy.

      The clinical hypothesis of this study is that the combination of panitumumab and FOLFIRI is a
      good treatment option in elderly patients with good performance status and RAS/BRAF wild-type
      unresectable mCRC. Another purpose of this clinical trial is to determine the RAS/BRAF
      mutation status in liquid biopsies at baseline and at the time of disease progression.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase II, multicentre, single-arm trial. Elderly patients with good performance status and
      RAS/BRAF wild-type unresectable mCRC will be evaluated before being included in this trial.
      Eligible patients will receive panitumumab plus FOLFIRI for disease control until disease
      progression, unacceptable toxicity, investigator decision or the patient's withdrawal of
      consent.

      Tumour response will be evaluated by investigators using RECIST criteria (Response Evaluation
      Criteria in Solid Tumours) version 1.1. Tumour response will be evaluated every 8 weeks until
      disease progression is documented. Disease response will be confirmed no less than 28 days
      after the criteria for response are first met. Radiographic progression of subjects with
      symptoms indicating disease progression will be evaluated at the time of symptom onset.

      Following disease progression, information will be collected on the subsequent lines of
      treatment chosen by the investigator and survival at follow-up visits held every 12 weeks (±
      4 weeks) until completion of the trial (approximately 24 months after inclusion of the last
      patient in the trial).

      A blood sample will be taken at baseline and at the time of disease progression in order to
      determine the RAS/BRAF mutation status.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 31, 2017</start_date>
  <completion_date type="Anticipated">February 28, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival at one year</measure>
    <time_frame>12 months after inclusion</time_frame>
    <description>Percentage of subjects still alive and progression free 12 months after inclusion in the study</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>42 months</time_frame>
    <description>Time (months) from inclusion in the trial until disease progression or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>42 months</time_frame>
    <description>Proportion of patients with an objective response (complete or partial response) according to RECIST 1.1 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>42 months</time_frame>
    <description>Proportion of patients with disease control (complete response, partial response or stable disease)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>42 months</time_frame>
    <description>Time (months) from the first confirmation of objective response according to RECIST 1.1 criteria until disease progression or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response</measure>
    <time_frame>18 months</time_frame>
    <description>Time (months) from inclusion in the trial until the date of the first confirmation of objective response according to RECIST 1.1 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>42 months</time_frame>
    <description>Time (months) from inclusion in the trial until death of the patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to treatment failure</measure>
    <time_frame>18 months</time_frame>
    <description>Time (months) from inclusion in the trial until progression, death or discontinuation due to toxicity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with early tumour shrinkage (ETS)</measure>
    <time_frame>2 months</time_frame>
    <description>Defined as tumour shrinkage ≥ 30% at the first tumour assessment based on RECIST 1.1 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depth of response (DpR)</measure>
    <time_frame>18 months</time_frame>
    <description>Measured as the maximum reduction ratio (percentage) of the tumour compared with baseline measurement (sum of diameters of the lesions) at the different assessments based on RECIST 1.1 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>42 months</time_frame>
    <description>Incidence and severity of adverse events. AEs description according to the NCI (National Cancer Institute) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03</description>
  </secondary_outcome>
  <other_outcome>
    <measure>RAS/BRAF conversion proportion</measure>
    <time_frame>At treatment initiation and at the time of PD (42 months)</time_frame>
    <description>Conversion rate of RAS/BRAF status at first-line treatment initiation and at the time of disease progression</description>
  </other_outcome>
  <other_outcome>
    <measure>RAS/BRAF mutations' detection proportion</measure>
    <time_frame>At baseline</time_frame>
    <description>Detection rate of RAS/BRAF mutations in liquid biopsies at baseline in subjects with RAS/BRAF wild-type mCRC according to the solid biopsy analysis</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Colorectal Neoplasms</condition>
  <condition>Colorectal Carcinoma</condition>
  <condition>Colorectal Cancer Metastatic</condition>
  <condition>Neoplasm Metastasis</condition>
  <arm_group>
    <arm_group_label>FOLFIRI + panitumumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will receive panitumumab plus FOLFIRI for disease control in 14-day cycles until disease progression, unacceptable toxicity, investigator's decision or patient withdrawal of consent, at the following doses:
Panitumumab: 6 mg/kg administered by intravenous (IV) infusion over 60 min on days 1 and 14 of every cycle just before administration of chemotherapy
FOLFIRI
Irinotecan: 180 mg/m2 as IV infusion over 90 min on day 1
Folinic acid: (leucovorin) 200-400 mg/m2 IV over 2 hours on day 1
5-FU: 400 mg/m2 bolus followed by 2400 mg/m2 IV continuous infusion over 46-48 hours on days 1 and 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Panitumumab</intervention_name>
    <description>Panitumumab 6 mg/kg will be administered by intravenous (IV) infusion over 60 min on days 1 and 14 of every cycle just before administration of chemotherapy</description>
    <arm_group_label>FOLFIRI + panitumumab</arm_group_label>
    <other_name>Vectibix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>Irinotecan 180 mg/m2 will be administered as IV infusion over 90 min on day 1</description>
    <arm_group_label>FOLFIRI + panitumumab</arm_group_label>
    <other_name>Any marketed</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Folinic acid</intervention_name>
    <description>Folinic acid 200-400 mg/m2 will be administered as IV infusion over 2 hours on day 1</description>
    <arm_group_label>FOLFIRI + panitumumab</arm_group_label>
    <other_name>Leucovorin</other_name>
    <other_name>Any marketed</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-FU</intervention_name>
    <description>5-FU will be administered IV 400 mg/m2 bolus followed by 2400 mg/m2 IV continuous infusion over 46-48 hours on days 1 and 2</description>
    <arm_group_label>FOLFIRI + panitumumab</arm_group_label>
    <other_name>5-fluorouracil</other_name>
    <other_name>Any marketed</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males or females ≥ 70 years,

          2. Able to understand, sign and date an informed consent form approved by the IEC,

          3. Histologically confirmed colorectal carcinoma with unresectable metastatic disease,

          4. RAS/BRAF wild-type status in solid biopsy confirmed prior to inclusion of the study,

          5. No previous treatment for metastatic disease,

          6. Patients starting therapy with FOLFIRI + panitumumab with a treatment aim other than
             achieving potential resectability of the disease,

          7. Independence in activities of daily living (ADL) based on the Katz Index and in
             instrumental activities of daily living (IAL) based on the Lawton Index,

          8. Having no or only one comorbidity according to the Charlson Comorbidity Index,

          9. Presence of at least one unidimensional measurable lesion ≥ 20 mm according to RECIST
             criteria (version 1.1),

         10. ECOG (Eastern Cooperative Oncology Group) performance status of 0-1,

         11. Adequate bone marrow function: neutrophils ≥ 1.5 x 10^9/l; platelets ≥ 100 x 10^9/l;
             haemoglobin ≥ 9 g/dl,

         12. Hepatic, renal and metabolic function as follows:

               1. Total bilirubin count ≤ 1.5 x ULN; ALT and AST &lt; 5 x ULN;

               2. Renal function, calculated creatinine clearance or 24-hour creatinine clearance ≥
                  50 ml/min;

               3. Magnesium &gt; LLN

        Exclusion Criteria:

          1. Diagnosed or suspected central nervous system (CNS) metastasis,

          2. History or presence of another malignancy, with the exception of curatively treated in
             situ carcinoma of the cervix or non-melanoma skin cancer or any curatively treated
             solid tumour, with no active disease or administration of treatment within 5 years
             prior to inclusion in the study,

          3. Prior treatment with irinotecan,

          4. Prior adjuvant chemotherapy for colorectal cancer terminated less than 6 months before
             metastatic disease was diagnosed,

          5. Prior anti-epidermal growth factor receptor (EGFR) antibody therapy (eg, cetuximab),
             anti- vascular endothelial growth factor (VEGF) or treatment with small molecule EGFR
             inhibitors (eg, erlotinib),

          6. Unresolved toxicities from prior systemic treatment that, in the investigator's
             opinion, make the patient unsuitable for inclusion,

          7. Hormone therapy, immunotherapy with experimental or approved antibodies/proteins (e.g.
             bevacizumab) ≤ 30 days prior to inclusion,

          8. Evidence of previous acute hypersensitivity reaction of any grade to any of the
             components of the treatment,

          9. History of interstitial lung disease or pulmonary fibrosis or signs of interstitial
             lung disease or pulmonary fibrosis on baseline CT,

         10. Presence of geriatric syndromes, defined as dementia, repeated falls, fecal
             incontinence or urinary incontinence,

         11. Acute or subacute bowel obstruction and/or active bowel disease or another bowel
             disease causing chronic diarrhoea (defined as diarrhoea of grade ≥ 2 according to the
             NCI (National Cancer Institute) Common Terminology Criteria for Adverse Events (CTCAE
             version 4.03),

         12. Significant cardiovascular disease, including unstable angina pectoris or myocardial
             infarction within 12 months prior to inclusion in the study,

         13. History of Gilbert's syndrome or dihydropyrimidine dehydrogenase deficiency,

         14. Positive test result for human immunodeficiency virus, hepatitis C virus, chronic
             active hepatitis B infection,

         15. Treatment for systemic infection within 14 days prior to the start of the study
             treatment,

         16. Clinically significant sensory peripheral neuropathy,

         17. Any concurrent disease that may increase the risk associated with study participation
             or may interfere with the interpretation of study results,

         18. Any investigational product within 30 days prior to inclusion,

         19. Surgery (not including diagnostic biopsy or the placement of a central line) and/or
             radiotherapy within 28 days prior to inclusion in the study,

         20. Males whose partner is of child-bearing age and who does not agree to use adequate
             contraceptive precautions, i.e. double-barrier methods (e.g. diaphragm plus condom) or
             abstinence for the duration of the study and for 1 month after the last administration
             of the study drug,

         21. Subjects who do not agree or are unable to meet the study requirements,

         22. Psychological, familial, sociological or geographical conditions potentially hampering
             compliance with the study protocol and the follow-up schedule. Such conditions should
             be discussed with the patient before enrolment in the clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jaime Feliu, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Universitario La Paz</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jaime Feliu, MD</last_name>
    <phone>+34 91 727 70 00</phone>
    <email>jaimefeliu@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anna Triginer</last_name>
    <phone>+34 93 434 44 12</phone>
    <email>secretaria@gemcad.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>ICO L´Hospitalet de Llobregat - Hospital Durán i Reynals</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08908</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gemma Soler González, MD</last_name>
      <email>gsoler@iconcologia.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Joan Despí-Moises Broggi</name>
      <address>
        <city>Sant Joan Despí</city>
        <state>Barcelona</state>
        <zip>08970</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gemma Soler González, MD</last_name>
      <email>gemma.solergonzalez@sanitatintegral.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro-Majadahonda</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Ruíz Casado, MD</last_name>
      <email>arcasado@salud.madrid.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Rey Juan Carlos</name>
      <address>
        <city>Móstoles</city>
        <state>Madrid</state>
        <zip>28933</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brezo Martínez-Amores, MD</last_name>
      <email>brezo.martinez@hospitalreyjuancarlos.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Estela Pineda Losada, MD</last_name>
      <email>epineda@clinic.cat</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Elda</name>
      <address>
        <city>Elda</city>
        <zip>03600</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristina Llorca Ferrándiz, MD</last_name>
      <email>cllorcaf@yahoo.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complejo Asistencial Universitario de León (CAULE)</name>
      <address>
        <city>León</city>
        <zip>24001</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmen Castañón López, MD</last_name>
      <email>carmencastanon@yahoo.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Arnau de Vilanova</name>
      <address>
        <city>Lleida</city>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonieta Salud Salvia, MD</last_name>
      <email>asaluds@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario la Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaime Feliu Batlle, MD</last_name>
      <email>jaimefeliu@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Integral Oncológico Clara Campal - Hospital HM Sanchinarro</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Cubillo Gracián, MD</last_name>
      <email>acubillo@hmhospitales.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Morales Meseguer</name>
      <address>
        <city>Murcia</city>
        <zip>30008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alberto Carmona Bayonas, MD</last_name>
      <email>alberto.carmonabayonas@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Son Espases</name>
      <address>
        <city>Palma</city>
        <zip>07020</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mónica Guillot Morales, MD</last_name>
      <email>monicam.guillot@ssib.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Parc Taulí</name>
      <address>
        <city>Sabadell</city>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ismael Macías Declara, MD</last_name>
      <email>imacias@tauli.cat</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario y Politécnico La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jorge Antonio Aparicio Urtasun, MD</last_name>
      <email>aparicio_josurt@gva.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario Lozano Blesa</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pilar Escudero Emperador, MD</last_name>
      <email>PILARESCUDERO@telefonica.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vicente Alonso Orduña, MD</last_name>
      <email>alonord@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>https://www.gemcad.es/</url>
    <description>GEMCAD web page</description>
  </link>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 2, 2017</study_first_submitted>
  <study_first_submitted_qc>May 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 5, 2017</study_first_posted>
  <last_update_submitted>February 14, 2018</last_update_submitted>
  <last_update_submitted_qc>February 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Clinical Trial, Phase II</keyword>
  <keyword>Elderly</keyword>
  <keyword>Aged</keyword>
  <keyword>Disease-Free Survival</keyword>
  <keyword>Safety</keyword>
  <keyword>Tolerability</keyword>
  <keyword>Chemotherapy regimen</keyword>
  <keyword>Monoclonal antibody</keyword>
  <keyword>FOLFIRI</keyword>
  <keyword>Panitumumab</keyword>
  <keyword>RAS/BRAF Wild-type</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

